GSK

As #WorldAMRAwarenessWeek comes to an end, we’re spotlighting the urgent need to improve access to antibiotics in lower-income countries. Through our collaboration with the Global Antibiotic R&D Partnership (GARDP), we’re helping strengthen access where the burden of antimicrobial resistance (#AMR) is greatest and resources are often most limited. In 2024, we committed €4.5 million to GARDP, and we’ve already made meaningful progress. Together, we’re deepening our understanding of how people access antibiotics and exploring innovative ways to bring both new and existing treatments to market. Hear from GSK’s Chief Global Health Officer, Thomas Breuer, MD, MSc, and Executive Director of GARDP, Dr Manica Balasegaram, as they discuss the realities of AMR in lower-income countries and why cross-sector collaboration is essential to tackling this global health challenge.

Eighty years ago, the Nobel Prize was awarded for the discovery of penicillin, the world’s first antibiotic. Sadly, we are now facing the potential loss of one of medicine’s greatest defenses. Yesterday, alongside our partners at the Fleming Initiative and the Ineos Oxford Institute for Antimicrobial Research, we brought together leaders in #AntimicrobialResistance at the Royal Society of Medicine to explore how we can strengthen our collective response to #AMR. The message was clear: innovation and collaboration are key to getting ahead of resistance and protecting the treatments that help protect us. Find out more about our latest work with the Fleming Initiative by reading this article on BBC News: https://gsk.to/3Mc7j8p #WorldAMRAwarenessWeek

Every day, infections that were once easy to treat are becoming harder to cure. #AntimicrobialResistance (#AMR) is one of the biggest health challenges we face, but we already have many of the tools to overcome it. Prevention, vaccines, diagnostics, innovation and smarter use of existing treatments can all make a real difference. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.

Did you know one quarter of patients hospitalised with a COPD exacerbation will return within 30 days? For the 390+ million people living with COPD, exacerbations mean terrifying breathlessness, hospital trips, loss of independence, and major life disruptions. On World COPD Day, we're focused on prevention – helping people avoid worsening symptoms and hospitalisations which can lead to long-term damage that can make everyday life harder. Earlier intervention and proactive disease management can help prevent exacerbations and hospitalisations in COPD and protect patients. That’s why, at GSK, we’re innovating to reshape the future of COPD care. Read more about why this is so important in our recent Politico article https://gsk.to/4oPVm73 #WorldCOPDDay2025 #SpeakUpForCOPD #AheadTogether

#News for #investors and #media: We have announced a collaboration with LTZ Therapeutics which could expand our oncology portfolio with up to four new therapies targeting haematologic cancers and solid tumours. The collaboration will advance the development of novel myeloid cell engagers (MCEs), an emerging class of immuno-oncology treatments designed to use the body’s immune system to recognise and kill cancer cells. https://gsk.to/4oMZpAP #GSK #AheadTogether

Together with the Fleming Initiative, we’re announcing six major research programmes to find new ways to get ahead of #AntimicrobialResistance or #AMR. This collaboration builds on GSK’s long-standing commitment to addressing drug-resistant infections. We have one of the largest pipelines in the industry, with over 30 projects that could help address AMR. While significant progress is being made, AMR remains a complex and urgent health and scientific challenge. That’s why GSK became the first founding partner of the Fleming Initiative, pledging £45m in 2024 to support its mission to tackle AMR around the world. With these new research programmes we’re combining scientific expertise with cutting-edge AI technology to accelerate AMR research. This includes funding for around 50 dedicated UK scientific and academic positions. Together, we’re building the partnerships and innovation needed to get ahead of resistance and protect the treatments that help protect us. Find out more: https://gsk.to/4oUk8mE

This #WorldHepatitisTestingWeek, hosted by the World Hepatitis Alliance, we’re shining a spotlight on the critical importance of testing for hepatitis B. Hepatitis B remains a major global health challenge, affecting over 254 million people worldwide and potentially leading to serious complications such as liver damage and cancer. Yet, many people living with hepatitis B are unaware of their condition, as symptoms often go unnoticed. We are proud to sponsor World Hepatitis Testing Week, introduced in response to the lack of progress in testing which remains one of the biggest barriers to meeting the WHO goal of eliminating viral hepatitis as a public health threat by 2030. At GSK, we recognise that timely and accurate testing is essential to support earlier diagnosis– a vital step toward reducing the long term impact of the disease. By raising visibility this week, we aim to build understanding of the importance of testing and encourage more conversations about early diagnosis and care for people living with hepatitis B.

Antibiotics are the foundation of modern medicine, but some are already losing their effectiveness as bacteria adapt. This is known as #AntimicrobialResistance or #AMR, and it’s one of the most urgent threats to public health we face today. At GSK we’re building on our 70-year legacy in infectious disease, turning cutting-edge science and technology into medicines and vaccines to get ahead of AMR. With our portfolio of innovative vaccines and medicines, we have the opportunity to make a real difference – helping to prevent and treat resistant bugs or aiming to reduce the likelihood of recurring infection. But innovation alone isn’t enough. We’re partnering to make sure vaccines and treatments reach the right patients at the right time, supported by better data and monitoring, and sustainable manufacturing. Together, we can protect the treatments that protect us. #WorldAMRAwarenessWeek

Exacerbations in COPD can have a major impact on patients, so early recognition and treatment are vital. Despite this, patients don’t always recognise them and underreporting of exacerbations is common – leading to under treatment and poorer outcomes. Our Open Up campaign encourages talking about exacerbations, which is why we have developed the COPD Exacerbation Recognition Tool (CERT), which we have licensed to GAAPP, a visual aid to help patients with COPD recognise the onset of an exacerbation and seek help promptly from their doctor. To find out more about CERT, visit https://gsk.to/4nX1Uzk